DailyPharm: Hanlim Pharmaceutical drives open innovation… expanding ophthalmic partners
Scale of ophthalmic drug technology transfer with RudaCure expands to over KRW 20 billion
Focused investment in macular degeneration biosimilars… partnerships with Altos Bio and others
Stable cash generation capacity connects to external investment… second-generation owner also supports
[DailyPharm = Reporter Lee Seok-joon] Hanlim Pharmaceutical is accelerating its open innovation drive. In particular, it has partnered with multiple companies to expand its core ophthalmic business. The scale of technology transfers with RudaCure has exceeded KRW 20 billion.
The expansion of the open innovation business is underpinned by Hanlim Pharmaceutical's strong operating cash generation capability. The company has been achieving an operating profit margin of around 15% for several years. The second-generation owner is also providing support.
Hanlim Pharmaceutical recently completed a technology transfer of RudaCure's corneal ulcer and corneal damage treatment candidate (RCI001U). Hanlim Pharmaceutical will hold domestic production and sales rights for RCI001U technology, while RudaCure will receive milestone payments including clinical trial approvals. The deal is worth KRW 7 billion (including an upfront payment of KRW 1 billion).
